Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475822 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL1480045 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL1033085 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL476050 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL419899 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL17090776 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL1556049 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL17090842 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL17090791 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL17090803 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784677-A1 | NON-COORDINATING ANION TYPE ACTIVATORS CONTAINING CATION HAVING LARGE ALKYL GROUPS | ExxonMobil Chemical Patents Inc. (US) | 2021-03-03 | — | — | EP | claimed |
| CN-112351987-A | Non-coordinating anionic activators containing cations with large alkyl groups | 埃克森美孚化学专利公司 | 2021-02-09 | — | — | CN | claimed |
| US-20190330139-A1 | Non-Coordinating Anion Type Activators Containing Cation Having Large Alkyl Groups | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-10-31 | — | — | US | claimed |
| EP-4222180-B1 | BIS(HETEROCYCLIC-OLATE) LEWIS BASE CATALYSTS AND METHODS THEREOF | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-112351987-B | Non-coordinating anionic activators containing cations having large alkyl groups | 埃克森美孚化学专利公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230357454-A1 | Methods for Delivery of Non-Aromatic Solutions to Polymerization Reactors | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732063-B2 | Lewis base catalysts and methods thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4222180-A1 | BIS(HETEROCYCLIC-OLATE) LEWIS BASE CATALYSTS AND METHODS THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4192888-A1 | METHODS FOR DELIVERY OF NON-AROMATIC SOLUTIONS TO POLYMERIZATION REACTORS | ExxonMobil Chemical Patents Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11572423-B2 | Processes for introduction of liquid activators in olefin polymerization reactions | EXXONMOBIL CHEMICALS PATENTS INC. (US) | 2023-02-07 | — | — | US | disclosed |
| EP-4110835-A1 | LEWIS BASE CATALYSTS AND METHODS THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20200254431-A1 | BIS(ARYL PHENOLATE) LEWIS BASE CATALYSTS AND METHODS THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200255556-A1 | Lewis Base Catalysts and Methods Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2020-08-13 | — | — | US | disclosed |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| US-20190330392-A1 | Non-Coordinating Anion Type Activators Containing Cation having Branched Alkyl Groups | EXXONMOBIL CHEMICALPATENTS INC. | 2019-10-31 | — | — | US | disclosed |
| US-20190330139-A1 | Non-Coordinating Anion Type Activators Containing Cation Having Large Alkyl Groups | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-10-31 | — | — | US | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2921499-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | POLM, POLRMT, RNMT | TSHR 495/4885THRB 936/4885DNM1 1776/4885 |
| US-11732063-B2 | Lewis base catalysts and methods thereof | TEC, ALOX12, ELL | TSHR 3939/4885THRB 4534/4885DNM1 1430/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | TSHR 551/4885THRB 1506/4885DNM1 2698/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | TSHR 411/4885THRB 1249/4885DNM1 1968/4885 |
| US-20190330139-A1 | Non-Coordinating Anion Type Activators Containing Cation Having Large Alkyl Groups | KCNK10, KCNK4, HCN4 | TSHR 3717/4885THRB 3969/4885DNM1 2834/4885 |
| US-20190330392-A1 | Non-Coordinating Anion Type Activators Containing Cation having Branched Alkyl Groups | KCNK10, HCN4, KCNK4 | TSHR 2117/4885THRB 2167/4885DNM1 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.